ContraVir Pharmaceuticals Inc.

NASDAQ: CTRVHealthcare / Biotechnology / USA
3.58+0.0200+0.56%Vol 139 1001Y Perf -94.38%
Jul 22nd, 2019 19:52
BID0.00 ASK0.00
Open3.59 Previous Close3.56
Pre-Market- After-Trading-
 - -%  - -%
Target Price
2.00 
Analyst Rating
— — 0.00
Potencial %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)3 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.00 
Earnings Date
23rd May 2018

Today's Price Range

3.533.70

52wk Range

3.5291.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-
1 Month
0.00%
3 Months
-59.73%
6 Months
1 391.67%
1 Year
-94.38%
3 Years
-60.04%
5 Years
-64.76%
10 Years
-

Name / TickerPriceChg.Chg.%
CTRV3.580.02000.56
AAPL218.75-4.3300-1.94
GOOG1 239.565.31000.43
MSFT137.32-0.2000-0.15
XOM72.640.66000.92
WFC48.920.27000.55
JNJ130.780.35000.27
FB187.19-0.2800-0.15
GE9.340.09000.97
JPM120.232.32001.97
Earnings HistoryEstimateReportedSurprise %
Q03 2018--0.03-
Q03 2017-0.14-0.0842.86
Q02 2017-0.14-0.1121.43
Q01 2017-0.14-0.137.14
Q04 2016-0.15-0.16-6.67
Q03 2016-0.23-0.1439.13
Q02 2016-0.25-0.2020.00
Q03 2015-0.15-0.33-120.00
Earnings Per EndEstimateRevision %Trend
6/2017 QR-0.090.00-
6/2017 QR-0.140.00-
6/2018 FY-0.410.00-
6/2018 FY-0.410.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume139 100
Shares Outstanding (in ths.)803
Trades Count487
Dollar Volume472 678
Avg. Volume376 703
Avg. Weekly Volume179 020
Avg. Monthly Volume475 720
Avg. Quarterly Volume825 013
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Rating---

ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

CEO: Robert T. Foster

Teplephone: +1 732 902-4000

Address: 399 Thornall Street, First Floor, Edison 08837, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

51%49%

Bearish Bullish

65%35%

News